Tema Oncology ETF Rating $27.46 +0.25 (+0.90%) As of 02:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Oncology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.85Holdings in CANC have an aggregate rating of Moderate Buy based on 361 analyst ratings issued in the past year covering 23 companies (70.8% of the portfolio).CANC Aggregate Price Target$27.46High Prediction$27.46Average Prediction$27.46Low Prediction$27.46Holdings in CANC have an aggregate price target of $27.46 and a range of $27.46 to $27.46 covering 23 companies (70.8% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy10 Buy rating(s)Moderate Buy10 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 23 CANC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.48%RVMDRevolution Medicines$44.50+2.2%4.2685 of 5 stars3.07$73.67 65.5%155.06%LLYEli Lilly and Company$755.51+0.5%4.997 of 5 stars2.67$939.61 24.4%24Analyst Downgrade4.66%GMABGenmab A/S$28.54+0.9%3.4315 of 5 stars2.70$39.25 37.6%10Positive News4.62%BBIOBridgeBio Pharma$51.69-1.3%4.3844 of 5 stars3.00$63.94 23.7%174.56%RHHBYRoche$42.68+2.1%N/A2.805News CoverageGap Up3.96%MRUSMerus$68.93+1.0%2.9993 of 5 stars3.08$90.54 31.3%133.72%ACLXArcellx$78.06+0.3%2.3029 of 5 stars3.13$114.31 46.4%15Positive NewsInsider Trade3.44%NUVLNuvalent$77.83+1.5%2.9441 of 5 stars3.09$119.50 53.5%113.17%EXELExelixis$39.89-0.5%4.6368 of 5 stars2.61$44.42 11.4%232.98%ONCBeOne Medicines$338.75+1.3%1.8358 of 5 stars3.11$336.30 -0.7%92.98%ABBVAbbVie$223.85+0.6%4.7781 of 5 stars2.93$223.45 -0.2%27Positive NewsAnalyst ForecastAnalyst Revision2.92%BMYBristol Myers Squibb$45.06+0.1%4.9275 of 5 stars2.24$56.38 25.1%21Positive NewsDividend AnnouncementAnalyst Revision2.68%ZLABZai Lab$33.13+1.5%2.8632 of 5 stars2.86$56.35 70.1%72.49%LEGNLegend Biotech$34.13+0.4%3.1637 of 5 stars2.91$74.22 117.5%11Positive News2.17%IDYAIDEAYA Biosciences$26.01+1.0%3.9019 of 5 stars2.82$43.36 66.7%171.98%ARGXargenex$740.22+0.5%4.0451 of 5 stars3.04$789.20 6.6%23Analyst Revision1.93%IMNMImmunome$9.74+3.7%2.1816 of 5 stars3.00$23.20 138.2%10Analyst ForecastGap Up1.92%SMMTSummit Therapeutics$19.10+1.1%3.178 of 5 stars2.56$31.87 66.9%181.91%SNDXSyndax Pharmaceuticals$14.81+0.2%3.8315 of 5 stars3.00$39.22 164.9%10Analyst Forecast1.88%GILDGilead Sciences$112.58-1.3%4.9578 of 5 stars2.89$117.17 4.1%28Positive News1.86%AMGNAmgen$285.07-0.1%4.6145 of 5 stars2.24$304.43 6.8%21Positive News1.85%MRKMerck & Co., Inc.$80.28-1.5%4.9993 of 5 stars2.33$106.41 32.6%21Positive News1.59%CELCCelcuity$52.88+1.9%1.4765 of 5 stars3.00$56.50 6.8%5Analyst ForecastGap Up This page (NASDAQ:CANC) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANC Stock Alerts